Regenxbio Inc (RGNX) Shares Bought by Arizona State Retirement System

Arizona State Retirement System lifted its stake in Regenxbio Inc (NASDAQ:RGNX) by 9.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 42,618 shares of the biotechnology company’s stock after buying an additional 3,618 shares during the period. Arizona State Retirement System’s holdings in Regenxbio were worth $3,218,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Regenxbio by 89.9% in the second quarter. BlackRock Inc. now owns 4,218,413 shares of the biotechnology company’s stock worth $302,671,000 after buying an additional 1,997,447 shares during the period. RTW Investments LP increased its holdings in shares of Regenxbio by 10.7% in the second quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock worth $149,208,000 after buying an additional 201,788 shares during the period. Northern Trust Corp increased its holdings in shares of Regenxbio by 21.2% in the second quarter. Northern Trust Corp now owns 359,040 shares of the biotechnology company’s stock worth $25,762,000 after buying an additional 62,849 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Regenxbio by 140.6% in the second quarter. Bank of New York Mellon Corp now owns 319,330 shares of the biotechnology company’s stock worth $22,911,000 after buying an additional 186,595 shares during the period. Finally, Botty Investors LLC increased its holdings in shares of Regenxbio by 9.0% in the third quarter. Botty Investors LLC now owns 224,187 shares of the biotechnology company’s stock worth $16,926,000 after buying an additional 18,473 shares during the period. Hedge funds and other institutional investors own 81.17% of the company’s stock.

Shares of NASDAQ:RGNX opened at $66.37 on Friday. Regenxbio Inc has a 1 year low of $23.25 and a 1 year high of $85.10. The stock has a market cap of $2.25 billion, a P/E ratio of -27.09, a price-to-earnings-growth ratio of 13.98 and a beta of -0.49.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.30. Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. The company had revenue of $5.31 million for the quarter. As a group, equities analysts forecast that Regenxbio Inc will post 1.64 earnings per share for the current year.

RGNX has been the topic of several analyst reports. TheStreet upgraded Regenxbio from a “d+” rating to a “c” rating in a report on Monday, September 17th. Bank of America downgraded Regenxbio from a “buy” rating to a “neutral” rating and boosted their price target for the company from $64.00 to $80.00 in a report on Monday, July 23rd. ValuEngine upgraded Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Friday, August 10th. Chardan Capital reduced their price target on Regenxbio from $130.00 to $127.50 and set a “buy” rating on the stock in a report on Wednesday, August 8th. Finally, Raymond James restated a “buy” rating on shares of Regenxbio in a report on Monday, October 29th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $84.07.

In other Regenxbio news, CFO Vittal Vasista sold 7,500 shares of Regenxbio stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $65.43, for a total transaction of $490,725.00. Following the sale, the chief financial officer now directly owns 123,584 shares of the company’s stock, valued at approximately $8,086,101.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Patrick J. Christmas sold 15,000 shares of Regenxbio stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $72.06, for a total value of $1,080,900.00. Following the sale, the senior vice president now directly owns 2,669 shares in the company, valued at $192,328.14. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 286,585 shares of company stock worth $18,814,681. 16.90% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://sportsperspectives.com/2018/11/10/regenxbio-inc-rgnx-shares-bought-by-arizona-state-retirement-system.html.

Regenxbio Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: Growth Stocks

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply